RESUMEN
LeRoy Walters was at the center of public debate about emerging biological technologies, even as "biotechnology" began to take root. He chaired advisory panels on human gene therapy, the human genome project, and patenting DNA for the congressional Office of Technology Assessment. He chaired the subcommittee on Human Gene Therapy for NIH's Recombinant DNA Advisory Committee. He was also a regular advisor to Congress, the executive branch, and academics concerned about policy governing emerging biotechnologies. In large part due to Prof. Walters, the Kennedy Institute of Ethics was one of the primary sources of talent in bioethics, including staff who populated policy and science agencies dealing with reproductive and genetic technologies, such as NIH and OTA. His legacy lies not only in his writings, but in those people, documents, and discussions that guided biotechnology policy in the United States for three decades.
Asunto(s)
Discusiones Bioéticas , Bioética , Biotecnología/ética , Genética/ética , Academias e Institutos/ética , Comités Consultivos/ética , Comités Consultivos/historia , Comités Consultivos/legislación & jurisprudencia , Biotecnología/historia , Biotecnología/tendencias , ADN Recombinante/historia , Gobierno Federal , Terapia Genética/ética , Terapia Genética/historia , Terapia Genética/legislación & jurisprudencia , Genética/legislación & jurisprudencia , Guías como Asunto , Historia del Siglo XX , Historia del Siglo XXI , Proyecto Genoma Humano/ética , Proyecto Genoma Humano/historia , Proyecto Genoma Humano/legislación & jurisprudencia , Humanos , Legislación como Asunto , Masculino , Política Pública/historia , Política Pública/legislación & jurisprudencia , Estados UnidosRESUMEN
ObjectivesãTo clarify the structure, applicability, and objectives of the current Japanese legislation for private information protection and research ethics and to examine the clauses of the related laws/regulations for academic research purposes.MethodsãThe research design is a descriptive study based on a systematic literature review. Using the "e-Gov" database, the laws/regulations relating to private information protection and research ethics that apply to medical research involving human subjects and human genome/gene analysis research were included in the research. The Drugs Law (Law No. 145 of 1960) and related GCP/GPSP regulations and laws/regulations on administrative organizations, management, and procedures were excluded. Furthermore, the guidelines and Q&A relating to these laws/regulations and all 47 prefectural regulations on private information protection have been selected from the websites of the related ministries, government organizations, and prefectures.ResultsãOur study demonstrated that the current legal system on private information protection consists of three layers and that the applicability of the laws/regulations in this area varies according to the type of research organization. Additionally, the applicability of the laws/regulations on research ethics is different depending on the research area. While the Private Information Protection Law (PIPL) for the private sector contains two objectives, PIPL for administrative organizations and PIPL for independent administrative organizations both include three objectives. For academic research purposes, PIPL for the private sector sets out a holistic exemption clause, whereas the other two PIPLs stipulate three specific exemption clauses. Furthermore, our research revealed that the clauses of the prefectural regulations demonstrated many variances.ConclusionãThis study suggests that the current Japanese legal system relating to private information protection could be defined as a "mixed model," wherein the laws/regulations concerned are not necessarily consistent. The protection of medical information is solely regulated by a few specific laws with a narrow scope of application; the ethical guidelines are not directly based on any laws; and identifying applicable laws/regulations, depending on the category of research organization, is complicated, especially in the case of collaborative research involving researchers from various organizations. Therefore, in the larger framework of legislation, it is indispensable to reconsider the protection of private medical information and its effective use, including the ethics of this process because of the sensitive and useful nature of private medical information.
Asunto(s)
Investigación Biomédica/ética , Investigación Biomédica/legislación & jurisprudencia , Privacidad/legislación & jurisprudencia , Proyecto Genoma Humano/ética , Proyecto Genoma Humano/legislación & jurisprudencia , Humanos , JapónRESUMEN
The Bermuda Principles for DNA sequence data sharing are an enduring legacy of the Human Genome Project (HGP). They were adopted by the HGP at a strategy meeting in Bermuda in February of 1996 and implemented in formal policies by early 1998, mandating daily release of HGP-funded DNA sequences into the public domain. The idea of daily sharing, we argue, emanated directly from strategies for large, goal-directed molecular biology projects first tested within the "community" of C. elegans researchers, and were introduced and defended for the HGP by the nematode biologists John Sulston and Robert Waterston. In the C. elegans community, and subsequently in the HGP, daily sharing served the pragmatic goals of quality control and project coordination. Yet in the HGP human genome, we also argue, the Bermuda Principles addressed concerns about gene patents impeding scientific advancement, and were aspirational and flexible in implementation and justification. They endured as an archetype for how rapid data sharing could be realized and rationalized, and permitted adaptation to the needs of various scientific communities. Yet in addition to the support of Sulston and Waterston, their adoption also depended on the clout of administrators at the US National Institutes of Health (NIH) and the UK nonprofit charity the Wellcome Trust, which together funded 90% of the HGP human sequencing effort. The other nations wishing to remain in the HGP consortium had to accommodate to the Bermuda Principles, requiring exceptions from incompatible existing or pending data access policies for publicly funded research in Germany, Japan, and France. We begin this story in 1963, with the biologist Sydney Brenner's proposal for a nematode research program at the Laboratory of Molecular Biology (LMB) at the University of Cambridge. We continue through 2003, with the completion of the HGP human reference genome, and conclude with observations about policy and the historiography of molecular biology.
Asunto(s)
Genómica/historia , Proyecto Genoma Humano/historia , Difusión de la Información/historia , Biología Molecular/historia , Política Organizacional , Bermudas , Genómica/legislación & jurisprudencia , Genómica/normas , Historia del Siglo XX , Historia del Siglo XXI , Proyecto Genoma Humano/legislación & jurisprudencia , Humanos , Difusión de la Información/legislación & jurisprudencia , Difusión de la Información/métodos , Reino Unido , Estados UnidosRESUMEN
May 21, 2018, marks the tenth anniversary of the signing into law of the Genetic Information Nondiscrimination Act. The Congressional deliberations for GINA were long and difficult. The original bill was introduced in 1995, and for many years, it did not look as if the bill would ever emerge from committee. Several of its provisions raised concerns for insurers, employers, and other stakeholders. After thirteen years, the controversial provisions were either deleted, revised, or clarified. At this ten-year mark, it is appropriate to take stock of GINA. In light of GINA's glacial legislative history, it is reasonable to start thinking about the necessity, wisdom, and feasibility of amending GINA or enacting new legislation to address unresolved or emerging issues of genetic discrimination and trends in genetics, genomics, precision medicine, and related technologies.
Asunto(s)
Privacidad Genética/legislación & jurisprudencia , Pruebas Genéticas/legislación & jurisprudencia , Genómica/ética , Genómica/métodos , Proyecto Genoma Humano/ética , Proyecto Genoma Humano/legislación & jurisprudencia , HumanosRESUMEN
We review emerging strategies to protect the privacy of research participants in international epigenome research: open consent, genome donation, registered access, automated procedures, and privacy-enhancing technologies.
Asunto(s)
Genómica/ética , Genómica/legislación & jurisprudencia , Difusión de la Información , Privacidad , Secuenciación de Nucleótidos de Alto Rendimiento , Proyecto Genoma Humano/ética , Proyecto Genoma Humano/legislación & jurisprudencia , Humanos , Análisis de Secuencia de ADNRESUMEN
PURPOSE: This review identifies the prominent topics in the literature pertaining to the ethical, legal, and social issues (ELSI) raised by research investigating personalized genomic medicine (PGM). METHODS: The abstracts of 953 articles extracted from scholarly databases and published during a 5-year period (2008-2012) were reviewed. A total of 299 articles met our research criteria and were organized thematically to assess the representation of ELSI issues for stakeholders, health specialties, journals, and empirical studies. RESULTS: ELSI analyses were published in both scientific and ethics journals. Investigational research comprised 45% of the literature reviewed (135 articles) and the remaining 55% (164 articles) comprised normative analyses. Traditional ELSI concerns dominated the discourse including discussions about disclosure of research results. In fact, there was a dramatic increase in the number of articles focused on the disclosure of research results and incidental findings to research participants. Few papers focused on particular disorders, the use of racial categories in research, international communities, or special populations (e.g., adolescents, elderly patients, or ethnic groups). CONCLUSION: Considering that strategies in personalized medicine increasingly target individuals' unique health conditions, environments, and ancestries, further analysis is needed on how ELSI scholarship can better serve the increasingly global, interdisciplinary, and diverse PGM research community.
Asunto(s)
Ética en Investigación , Proyecto Genoma Humano/ética , Proyecto Genoma Humano/legislación & jurisprudencia , Medicina de Precisión/ética , Responsabilidad Social , Teoría Ética , Genoma Humano , Genómica , Humanos , Valores SocialesRESUMEN
Public health policy works best when grounded in firm public health standards of evidence and widely shared social values. In this article, we argue for incorporating a specific method of ethical deliberation--deliberative public bioethics--into public health. We describe how deliberative public bioethics is a method of engagement that can be helpful in public health. Although medical, research, and public health ethics can be considered some of what bioethics addresses, deliberative public bioethics offers both a how and where. Using the Human Genome Project Ethical, Legal, and Social Implications program as an example of effective incorporation of deliberative processes to integrate ethics into public health policy, we examine how deliberative public bioethics can integrate both public health and bioethics perspectives into three areas of public health practice: research, education, and health policy. We then offer recommendations for future collaborations that integrate deliberative methods into public health policy and practice.
Asunto(s)
Proyecto Genoma Humano/ética , Salud Pública/ética , Bioética , Conducta Cooperativa , Proyecto Genoma Humano/legislación & jurisprudencia , Proyecto Genoma Humano/organización & administración , Humanos , Salud Pública/legislación & jurisprudencia , Política Pública , Estados UnidosRESUMEN
While bioethics as a field has concerned itself with methodological issues since the early years, there has been no systematic examination of how ethics is incorporated into research on the Ethical, Legal and Social Implications (ELSI) of the Human Genome Project. Yet ELSI research may bear a particular burden of investigating and substantiating its methods given public funding, an explicitly cross-disciplinary approach, and the perceived significance of adequate responsiveness to advances in genomics. We undertook a qualitative content analysis of a sample of ELSI publications appearing between 2003 and 2008 with the aim of better understanding the methods, aims, and approaches to ethics that ELSI researchers employ. We found that the aims of ethics within ELSI are largely prescriptive and address multiple groups. We also found that the bioethics methods used in the ELSI literature are both diverse between publications and multiple within publications, but are usually not themselves discussed or employed as suggested by bioethics method proponents. Ethics in ELSI is also sometimes undistinguished from related inquiries (such as social, legal, or political investigations).
Asunto(s)
Proyecto Genoma Humano/ética , Proyecto Genoma Humano/legislación & jurisprudencia , Informe de Investigación , Valores Sociales , Teoría Ética , Genoma Humano , Humanos , Responsabilidad SocialRESUMEN
The Human Variome Project (http://www.humanvariomeproject.org) is an international effort aiming to systematically collect and share information on all human genetic variation. The two main pillars of this effort are gene/disease-specific databases and a network of Human Variome Project Country Nodes. The latter are nationwide efforts to document the genomic variation reported within a specific population. The development and successful operation of the Human Variome Project Country Nodes are of utmost importance to the success of Human Variome Project's aims and goals because they not only allow the genetic burden of disease to be quantified in different countries, but also provide diagnosticians and researchers access to an up-to-date resource that will assist them in their daily clinical practice and biomedical research, respectively. Here, we report the discussions and recommendations that resulted from the inaugural meeting of the International Confederation of Countries Advisory Council, held on 12th December 2011, during the 2011 Human Variome Project Beijing Meeting. We discuss the steps necessary to maximize the impact of the Country Node effort for developing regional and country-specific clinical genetics resources and summarize a few well-coordinated genetic data collection initiatives that would serve as paradigms for similar projects.
Asunto(s)
Variación Genética , Genoma Humano , Proyecto Genoma Humano , Guías como Asunto , Proyecto Genoma Humano/economía , Proyecto Genoma Humano/ética , Proyecto Genoma Humano/legislación & jurisprudencia , Humanos , Cooperación Internacional , Sistema de Registros , Programas InformáticosAsunto(s)
Acceso a la Información/ética , Investigación Biomédica/ética , Bases de Datos como Asunto/ética , Sector Privado/ética , Acceso a la Información/legislación & jurisprudencia , Animales , Investigación Biomédica/economía , Investigación Biomédica/tendencias , Seguridad Computacional/economía , Seguridad Computacional/ética , Seguridad Computacional/tendencias , Bases de Datos como Asunto/economía , Bases de Datos como Asunto/tendencias , Bases de Datos de Ácidos Nucleicos/economía , Bases de Datos de Ácidos Nucleicos/ética , Bases de Datos de Ácidos Nucleicos/tendencias , Proyecto Genoma Humano/economía , Proyecto Genoma Humano/ética , Proyecto Genoma Humano/legislación & jurisprudencia , Humanos , National Institutes of Health (U.S.)/economía , National Institutes of Health (U.S.)/ética , National Institutes of Health (U.S.)/legislación & jurisprudencia , Revisión de la Investigación por Pares/ética , Revisión de la Investigación por Pares/normas , Revisión de la Investigación por Pares/tendencias , Publicaciones Periódicas como Asunto/ética , Sector Privado/economía , Sector Privado/tendencias , Apoyo a la Investigación como Asunto/economía , Apoyo a la Investigación como Asunto/ética , Apoyo a la Investigación como Asunto/tendencias , Estados UnidosRESUMEN
BACKGROUND: The completion of the Human Genome Project, and recent breakthroughs in identifying the genes both directly responsible for and contributing to the severity of specific diseases and disabilities in humans offer great potential for future health care. AIM: The aim of the paper is to inform the health information community of these developments in order to foster debate over their wide-reaching implications. METHODS: The article outlines recent research in this area and explains how our growing understanding opens the way for improved diagnosis of disease, detection of possible predisposition to specific diseases, the interaction between genetics and environmental aspects such as diet, as well as enabling gene therapy and preventative actions. This new knowledge also opens the way for the use of pharmacogenetic information to enhance the efficacy of pharmaceuticals and to avoid toxic reactions. RESULTS: These advances have significant social, legal and ethical implications. Most countries have limited legislative control over the use and protection of genetic information about individuals. CONCLUSION: There is a role for health information professionals to play in promoting wider public knowledge of genetic research and its implications, in fostering public debate on key issues, and in seeking clearer policies in the health sector concerning the use of genetic information about individuals.
Asunto(s)
Servicios Genéticos/organización & administración , Conocimientos, Actitudes y Práctica en Salud , Proyecto Genoma Humano/organización & administración , Difusión de la Información , Competencia Profesional , Asesoramiento Genético/organización & administración , Predisposición Genética a la Enfermedad , Servicios Genéticos/ética , Servicios Genéticos/legislación & jurisprudencia , Técnicas Genéticas , Proyecto Genoma Humano/ética , Proyecto Genoma Humano/legislación & jurisprudencia , Humanos , Rol ProfesionalRESUMEN
The paper reconstructs the governance of genomics by sketching the main features, modes of operation and tactics of the emerging genomics apparatus. Genomic governance in the 20th century is characterized by the simultaneous operation of a process of the stabilization of knowledge regimes, in particular via patenting. Furthermore, we observe a heterogenization and globalization of the actors and knowledge creating systems in genomics governance. A variety of different mechanisms and strategies of governance are mobilized simultaneously. The transition of governing via risk to governance by uncertainty is another important feature of contemporary genomics governance. The implications of these trends for the regulation of genomics are considerable and might lead to the emergence of new patterns and spaces of conflict and controversy. The governance of genomics in the 21st century could become a more complex challenge than currently anticipated by many policy makers and the scientific community.